|
| Matthew Ravalin | Department of Pharmaceutical Chemistry, University of California at San Francisco |
| Jason E Gestwicki | Department of Pharmaceutical Chemistry, University of California at San Francisco |
| Jason E Gestwicki | Institute for Neurodegenerative Diseases, University of California at San Francisco |
| Charles S Craik | Department of Pharmaceutical Chemistry, University of California at San Francisco |